Pharmaxis Ltd (AU:SNT) has released an update.
Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Syntara Limited has announced promising interim results from its Phase 2 trial of SNT-5505 for myelofibrosis, showing significant symptom improvement and spleen volume reduction in patients. The trial, which combines SNT-5505 with ruxolitinib, highlights the potential for long-term benefits and an excellent safety profile, differentiating it from existing treatments. Investors may find the positive data and potential for future partnerships with global entities an intriguing development.
For further insights into AU:SNT stock, check out TipRanks’ Stock Analysis page.
